[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"brain-abscess\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:brain-abscess":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,44,69,96,150],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100629788","circulating-cell-free-dna-for-brain-abscess-diagnosis-a-pilot-study-100629788",false,"NCT07479225","Circulating Cell-Free DNA for Brain Abscess Diagnosis: A Pilot Study","Assessment of Circulating Cell-Free DNA for the Microbiological Diagnosis of Brain Abscesses: A Pilot Proof-of-Concept Study","METABCES-PoC","Inclusion Criteria:\n\n* Participant ≥ 18 years of age.\n* Participant presenting with a brain abscess requiring neurosurgical\n* Signed Informed Consent\n* Covered by health insurance\n\nExclusion Criteria:\n\n* Participant in exclusion period for another study\n* Participant referred to in articles L1121-5 to L1121-8 of the CSP (corresponding to all protected persons : pregnant woman, parturient, breastfeeding mother, person deprived of liberty by judicial or administrative decision, persons undergoing psychiatric care under articles L.3212-1 and L.3213-1 who do not fall under article L.1121-8, persons admitted to a healthcare or social institution for purposes other than research, minors, person under legal protection or unable to express consent).\n* Staff members with a hierarchical relationship to the principal investigator","ALL","18 Years",{"count":20,"type":21},15,"ESTIMATED","INTERVENTIONAL",[24],"NA","Brain abscess is a severe intracranial infection associated with significant morbidity and mortality. Standard management combines neurosurgical intervention, when feasible, with prolonged intravenous antibiotic therapy. Neurosurgical procedures, such as surgical drainage or stereotactic aspiration, play a key role in reducing intracranial pressure, decreasing the infectious burden, and obtaining samples for microbiological identification.\n\nHowever, neurosurgical intervention is not always possible due to technical limitations or patien related contrindications. In these situations, microbiological documentation becomes particularly challenging. Conventional diagnostic methods have limited sensitivity, with blood cultures and lumbar puncture yielding positive results in only about 25% of brain abscess cases.\n\nRecent advances in infectious disease diagnostics have introduced metagenomic approaches that may improve pathogen detection. Studies have shown that metagenomic analysis of operative samples can provide more comprehensive microbiological documentation than conventional culture-based methods. In addition, next-generation sequencing (NGS) of circulating microbial cell-free DNA in blood enables the detection of short microbial DNA fragments with a short half-life, reflecting active infection. This technology has already demonstrated promising results in clinical situations where microbiological documentation is difficult, such as febrile neutropenia. The present study aims to evaluate the performance of this approach in patients with brain abscess.",[27],"Brain Abscess",[27,29,30],"Cell-Free DNA","Metagenomics","NOT_YET_RECRUITING","2026-03-12",{"date":34,"type":35},"2026-03-18","ACTUAL",{"date":37,"type":21},"2026-04-01",{"date":39,"type":21},"2028-03-31",{"name":41,"class":42},"University Hospital, Grenoble","OTHER",2,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":17,"minAge":50,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":54,"conditions":55,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":68},"100434531","cognitive-function-and-fatigue-after-brain-abscess-100434531","NCT04938362","Cognitive Function and Fatigue After Brain Abscess","Inclusion criteria:\n\n• Patients who have completed treatment for brain abscess and who agree to participate.\n\nExclusion criteria:\n\n* Patients who cannot undergo neuropsychological investigation due to unconsciousness\n* Patients who cannot undergo neuropsychological investigation, being mentally too ill\n* Patients who suffer from dementia\n* Patients who cannot undergo FDG-PET due to claustrophobia\n* Patients who cannot undergo EEG due to panic attacks\n* Age under 16.","16 Years",{"count":52,"type":21},50,"OBSERVATIONAL","Brain abscess is a focal bacterial or fungal infection of the brain. Treatment is neurosurgical drainage of pus followed by long-term antibiotic treatment. In spite of successful treatment of the infection, long-term cognitive problems or mental fatigue may ensue. The reason for this dysfunction may be a continuing inflammatory state or damage to brain tissue caused by the abscess. The investigators will evaluate these possibilities with the use of \\[18F\\]deoxyglucose-positron emission tomography (FDG-PET) and electroencephalography (EEG) in patients who have been treated for brain abscess and who experience cognitive problems and\u002For fatigue. FDG-PET may identify both inflammation and altered neuronal activity (the latter indicating damage to brain tissue), and EEG may identify altered neuronal activity, including changes in neuronal network activity.",[27,56,57],"Fatigue","Cognitive Dysfunction","RECRUITING","2025-07-01",{"date":61,"type":35},"2025-07-04",{"date":63,"type":35},"2020-01-01",{"date":65,"type":21},"2030-12-31",{"name":67,"class":42},"University of Oslo",1,{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":75,"eligibilityCriteria":76,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":77,"targetDuration":4,"studyType":22,"phases":79,"briefSummary":81,"conditions":82,"keywords":84,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":95},"100373321","phase-4-partial-oral-antibiotic-treatment-for-bacterial-brain-abscess-100373321","NCT04140903","Partial Oral Antibiotic Treatment for Bacterial Brain Abscess","Partial Oral Antibiotic Treatment for Bacterial Brain Abscess: an Open-label Randomised Non-inferiority Trial","ORAL","Inclusion Criteria:\n\n1. A clinical presentation (e.g. headache, neurological deficit or fever) and cranial imaging (CT or MRI) consistent with brain abscess AND\n2. The physician responsible for the patient decides to treat the patient for bacterial brain abscess AND\n3. Ability to take and absorb oral medications (including by nasogastric tube) AND\n4. To have received relevant antibiotic therapy for bacterial brain abscess for 14 consecutive days before randomisation AND\n5. Expected to be treated with antibiotic therapy for at least another 14 days after time of randomisation AND\n6. No progression in symptom intensity or occurrence of new-onset neurological symptoms (excluding seizures) within five days before time of randomisation.\n\nExclusion Criteria (patients fulfilling either criteria):\n\n1. Expected substantially reduced compliance with treatment (e.g. IV drug abuse)\n2. Pregnancy (proven by positive urine or plasma human chorionic gonadotropin test in fertile women \\\u003C50 years of age)\n3. Concomitant (empirical) brain abscess treatment for tuberculosis, nocardiosis, Pseudomonas spp., fungi, toxoplasmosis or other CNS parasites\n4. Device related brain abscesses (e.g. deep brain stimulators, ventriculo-peritoneal shunts)\n5. Severe immuno-compromise defined as ongoing need for biological- or chemotherapy, prednisolone \\>20 mg\u002Fday for 14 days or longer, uncontrolled HIV\u002FAIDS, haematological malignancies, and organ transplant recipients\n6. Concomitant or unrelated infections necessitating IV antibiotics beyond seven days of duration after time of randomisation\n7. Previous enrolment into this trial",{"count":78,"type":21},400,[80],"PHASE4","The investigators aim to determine if oral antibiotics are clinically acceptable as treatment of brain abscess. Following 2 weeks of standard intravenous antibiotic therapy, half of patients will continue with this treatment for another 4 weeks or longer while the other half will be assigned to oral antibiotics for the remaining duration of treatment.",[27,83],"Cerebral Abscess",[85],"Oral antibiotics","2025-01-28",{"date":88,"type":35},"2025-01-30",{"date":90,"type":35},"2020-11-06",{"date":92,"type":21},"2028-08-31",{"name":94,"class":42},"Henrik Nielsen",4,{"id":97,"slug":98,"hasResults":11,"nctId":99,"briefTitle":100,"officialTitle":101,"acronym":102,"eligibilityCriteria":103,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":104,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":106,"conditions":107,"keywords":123,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":140,"lastUpdatePostDateStruct":141,"startDateStruct":143,"completionDateStruct":145,"leadSponsor":147,"locationsCount":52},"100284234","fosfomycin-iv-for-treatment-of-severely-infected-patients-100284234","NCT02979951","Fosfomycin I.v. for Treatment of Severely Infected Patients","An International, Multicentre, Non-comparative, Non-interventional, Prospective Clinical Registry to Evaluate the Clinical Outcome and Safety of the Treatment of Severely Infected Patients with Fosfomycin I.v.","FORTRESS","Inclusion Criteria:\n\n* Male or female patients aged ≥ 18 years\n* Treatment with fosfomycin according to the (national) Summary of Product Characteristics (SmPC) of fosfomycin i.v.\n* Patients with osteomyelitis, complicated urinary tract infection, nosocomial lower respiratory tract infection, bacterial meningitis\u002Fcentral nervous system infection, bacteraemia\u002Fsepsis, skin and soft tissue infection, endocarditis or other infection, each as far as covered by the respective nationally relevant SmPC\n* Written informed consent of the participant (or person in charge in case of patients incapable of giving consent)\n\nExclusion Criteria:\n\n* Previous documentation of the patient in the present study\n* Patients participating in an interventional clinical trial\n* Patients with known hypersensitivity to fosfomycin or any of the excipients\n* Terminally ill patients\n* Patients with \"do not resuscitate order\"\n* Palliative treatment approach\n* Failure of \\> 3 of the following organ systems: respiratory system, nervous system, cardiovascular system, liver, coagulation, kidney\n* Manifest Human Immunodeficiency Virus (HIV) disease (Acquired Immunodeficiency Syndrome, AIDS)\n* Fosfomycin treatment as 4th line treatment or at later stage\n* Patients with involvement of fungi or mycobacteria in the targeted infection",{"count":105,"type":21},1000,"The purpose of this European, multicentric, prospective, non-interventional study is to document and evaluate the efficacy and safety of the treatment of severely infected patients with intravenously administered fosfomycin, including patients with osteomyelitis, complicated urinary tract infection, nosocomial lower respiratory tract infection, bacterial meningitis\u002Fcentral nervous system infection, bacteraemia\u002Fsepsis, skin and soft tissue infection, endocarditis or other infections, each as far as covered by the respective nationally relevant SmPC.",[108,109,110,111,112,113,27,114,115,116,117,118,119,120,121,122],"Bacterial Infections","Bone Diseases, Infectious","Osteomyelitis","Central Nervous System Bacterial Infections","Meningitis, Bacterial","Encephalitis","Urinary Tract Infections","Respiratory Tract Infections","Pneumonia, Bacterial","Skin Diseases, Bacterial","Soft Tissue Infections","Intraabdominal Infections","Sepsis","Bacteremia","Endocarditis, Bacterial",[124,125,126,127,128,129,130,131,132,133,108,134,135,109,110,111,112,113,27,114,115,116,117,118,119,120,121,122,136,137,138,139],"Observational Study","Non-Interventional Study","Registries","Prospective","Monitored","Multicentric","International","Fosfomycin","Infectofos","Fomicyt","Gram-Negative Bacterial Infections","Gram-Positive Bacterial Infections","Treatment Outcome","Clinical Efficacy","Microbiological Efficacy","Safety","2024-09-27",{"date":142,"type":35},"2024-10-01",{"date":144,"type":4},"2016-12",{"date":146,"type":21},"2030-12",{"name":148,"class":149},"Infectopharm Arzneimittel GmbH","INDUSTRY",{"id":151,"slug":152,"hasResults":11,"nctId":153,"briefTitle":154,"officialTitle":155,"acronym":156,"eligibilityCriteria":157,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":158,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":160,"conditions":161,"keywords":171,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":177,"lastUpdatePostDateStruct":178,"startDateStruct":180,"completionDateStruct":182,"leadSponsor":184,"locationsCount":186},"100317883","central-nervous-system-infections-in-denmark-100317883","NCT03418441","Central Nervous System Infections in Denmark","Danish Study Group of Infections of the Brain: A Nationwide Prospective Observational Cohort Study of All Central Nervous System Infections in Adults at Departments of Infectious Diseases in Denmark","DASGIB","Definitions of central nervous system infections:\n\nFor all cases with unproven aetiologies no alternative diagnosis than CNS infection is thought more likely after completed multidisciplinary diagnostic work-up.\n\nViral meningitis inclusion criteria\n\n\\- All patients have to have a clinical presentation consistent with non-bacterial meningitis (e.g. headache, neck stiffness, photo- or phonophobia, fever)\n\nand\n\nCerebrospinal fluid leukocytes\\>10 cells\u002Fml\n\nPatients with viral meningitis with undetermined pathogen have to have:\n\n* CSF leukocytes\\> 10\u002FmL and no other more probable diagnosis assessed by the local investigator.\n\nIn case of doubt, patients are discussed with the DASGIB secretary and chair or at meetings.\n\nBacterial meningitis inclusion criteria - All patients have to have a clinical presentation consistent with bacterial meningitis (e.g. headache, neck stiffness, fever, altered mental status)\n\nand\n\nProven bacterial aetiology (CSF or blood culture\u002FDNA based technology or antigen tests)\n\nPatients with bacterial meningitis in whom the bacteria cannot not be cultured or identified by DNA-based technologies have to have:\n\n\\- CSF leukocytes\\> 10\u002FmL and no other more probable diagnosis assessed by the local investigator.\n\nIn case of doubt, patients are discussed with the DASGIB secretary and chair or at meetings.\n\nEncephalitis inclusion criteria - All patients have to have a clinical presentation consistent with encephalitis (e.g. headache, fever, focal neurological deficit, altered mental status \\>24 hours) as defined by the International Encephalitis Consortium (Venkatesan A et al., Clin Infect Dis 2013; doi:10.1093\u002Fcid\u002Fcit458.).\n\nEncephalitis exclusion criteria\n\n\\- We exclude cases of proven or suspected autoimmune encephalitis.\n\nPrimary brain abscess inclusion criteria\n\n\\- All patient have a clinical presentation consistent with brain abscess (e.g. headache, focal neurological deficit, mass lesion on cranial imaging)\n\nand\n\n\\- Proven microbiological aetiology by culture\u002FDNA-based technology from pus from brain abscess or blood or CSF\n\nor\n\n\\- Aspiration of pus from the brain abscess\n\nor\n\n\\- Response to antimicrobial treatment\n\nor\n\n\\- Tumour ruled out\n\nor\n\n\\- Tumour thought less probable than abscess on MRI using diffusion weighted imaging (DWI) and apparent diffusion coefficient (ADC) sequences.\n\nLyme neuroborreliosis inclusion criteria\n\n\\- A clinical presentation consistent with neuroborreliosis (e.g. radiculopathy)\n\nand\n\n\\- CSF pleocytosis\\>10 leukocytes\u002FmL\n\nand\n\n\\- Positive intrathecal B.burgdorferi antibody production index.\n\nNeurosyphilis inclusion criteria - A clinical presentation consistent with neurosyphilis (e.g. 'encephalitis-like symptoms', dementia, ocular or otogenic syphilis)\n\nand either\n\n\\- Positive syphilis serology in serum combined with CSF leukocytes\\>10\u002FmL\n\nor\n\n\\- CSF syphilis antibodies.",{"count":159,"type":21},1900,"The Danish Study Group of Infections of the Brain is a collaboration between all departments of infectious diseases in Denmark. The investigators aim to monitor epidemiological trends in central nervous system (CNS) infections by a prospective registration of clinical characteristics and outcome of all adult (\\>17 years of age) patients with community-acquired CNS infections diagnosed and\u002For treated at departments of infectious diseases in Denmark since 1st of January 2015.",[162,163,164,165,113,27,166,167,168,169,83,170],"Central Nervous System Infections","Bacterial Meningitis","Viral Meningitis","Aseptic Meningitis","Neuroborreliosis","Neurosyphilis","Lyme Disease","Tertiary Syphilis","Meningitis",[172,173,162,170,113,174,175,166,167,176],"Nationwide prospective observational cohort study","Epidemiology","Brain abscess","Lyme disease","Tertiary syphilis","2024-05-15",{"date":179,"type":35},"2024-05-16",{"date":181,"type":35},"2015-01-01",{"date":183,"type":21},"2030-01-01",{"name":185,"class":42},"Aalborg University Hospital",8]